Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02910583
Title Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Acronym Captivate
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | POL | NZL | ITA | ESP | AUS


No variant requirements are available.